We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
XTLB

Price
1.13
Stock movement down
-0.03 (-2.22%)
Company name
XTL Biopharmaceuticals Ltd ADR
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
5.99M
Ent value
5.15M
Price/Sales
-
Price/Book
2.70
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-60.14%
3 year return
-20.27%
5 year return
2.01%
10 year return
-24.77%
Last updated: 2025-04-15

iO Charts is a Seeking Alpha partner

DIVIDENDS

XTLB does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book2.70
EV to Sales-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count5.45M
EPS (TTM)-0.21
FCF per share (TTM)-

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-714.00K
Net income (TTM)-1.15M
EPS (TTM)-0.21
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash1.07M
Net receivables150.00K
Total current assets2.55M
Goodwill0.00
Intangible assets380.00K
Property, plant and equipment0.00
Total assets2.93M
Accounts payable223.00K
Short/Current long term debt0.00
Total current liabilities223.00K
Total liabilities223.00K
Shareholder's equity2.22M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)0.00
Capital expenditures (TTM)0.00
Free cash flow (TTM)0.00
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-51.67%
Return on Assets-47.28%
Return on Invested Capital-51.67%
Cash Return on Invested Capital-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.11
Daily high1.11
Daily low1.10
Daily Volume1K
All-time high571.00
1y analyst estimate30.00
Beta1.00
EPS (TTM)-0.21
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
XTLBS&P500
Current price drop from All-time high-99.80%-12.89%
Highest price drop-99.87%-56.47%
Date of highest drop3 Nov 20239 Mar 2009
Avg drop from high-92.35%-11.07%
Avg time to new high2160 days12 days
Max time to new high4317 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
XTLB (XTL Biopharmaceuticals Ltd ADR) company logo
Marketcap
5.99M
Marketcap category
Small-cap
Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Employees
0
Investor relations
-
SEC filings
CEO
Joshua Levine
Country
USA
City
Raanana
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...